Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Staidson (Beijing) Biopharmaceuticals Co., Ltd
With
Beijing Defengrui Biotechnology Co. Ltd
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18≤ age ≤60, 18 kg/m2 ≤BMI ≤28 kg/m2, male or female;
Diagnosed with 2019-nCoV infection and classified clinically as mild or general;
Agreed not to participate in other clinical studies before completing this study;
With the subject's consent and signed informed consent form by the subject or his/her legal representative.
You may not be if
Diagnosed with 2019-nCoV infection and classified clinically as severe or critical severe; severe pneumonia or acute respiratory distress syndrome, sepsis and septic shock;
The disease would deteriorate significantly within 48 hours judged by the investigators;
Immunodeficiency or immune related diseases not suitable for participation judged by the investigators (such as autoimmune diseases, IgG4 related diseases, allergic alveolitis, vasculitis, etc);
Lymphocyte count \<0.5×109/L;
Neutropenia history (neutrophil absolute count was less than 2×109/L in adults), except for infection;
D- dimer \>2000 µg/L;
Severe history of lung diseases, such as chronic obstructive pulmonary disease, lung cancer, tuberculosis, etc., history of heart disease: unstable angina pectoris, myocardial infarction, cardiac surgery, cardiac function≥ grade 3 (NYHA classification), serious history of liver disease (such as Child Pugh score ≥grade C), serious renal disease history, such as renal insufficiency (GFR ≤ 15ml/min/1.73m2), etc;
The subjects used the following drugs within 2 weeks (including 2 weeks) before screening:
1. Calcineurin inhibitors (such as cyclosporin and tacrolimus);
2. Proliferation inhibitors (such as everolimus, sirolimus, etc);
